팜젠사이언스

004720KOSPI의약품 제조업

46.3 / 100

Reference Date: 2026-06-10

Financial Score14.5 / 40

News Sentiment18.8 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Plunged 22.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Palmgen Science operates in pharmaceuticals, healthcare, and real estate leasing, achieving 16.54 billion KRW in pharmaceutical sales and 650 million KRW in healthcare sales in 2025. Key products include Esomax (for digestive disorders), Bardifin (hypertension treatment), and Kvasitin (hyperlipidemia treatment), with the company enhancing competitiveness through new drug development and quality improvements.

Number of Employees

229people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

0.48Industry Average 0.895.5Point

Lower than industry avg (good)

ROE

-58.95Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

10.55Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼13.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.4% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 0Negative 1Average Sentiment Score 75

Positive
팜젠사이언스, 티에스바이오와 재생의료 사업 MOU 체결
팜젠사이언스가 티에스바이오와의 MOU를 통해 재생의료 및 바이오의약품 분야로 사업 영역을 확장함으로써 긍정적인 성장 전망을 보임.
Positive
[혁신형 제약기업 점검]① 준혁신형에 쏠린 눈…약가 방어권 된 인증.....
팜젠사이언스는 준혁신형 제약기업 인증으로 인해 경제적 이점과 시장 지위 강화를 기대하고 있다.
Negative
[제약사 리포트] 팜젠사이언스, R&D 확대 본격화…비용 증가 부담
팜젠사이언스의 외형 성장에도 불구하고 R&D 비용 증가로 인해 수익성이 악화되었다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,090Won52-week high 4,92552-week low 3,080

1-month return0.0Point

1m -22.75% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral[기재정정]사업보고서 (2025.12)2026-05-15
Neutral분기보고서 (2026.03)2026-05-15
Neutral주식등의대량보유상황보고서(일반)2026-05-12
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-12